Focused on Cures

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients

INNOVATIVE

Technology

Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

We are the first company to remove HIV genomes from animals and generate functional cures for HIV.

NOVEL

Approach

SAFE

Targets non-human viral genomes minimizing chance of off-target cuts

CURATIVE

Removes non-human DNA to return the genome to normal or near-normal

EFFICIENT

Excision products require one-time gene edit to remove the viral genome permanently

“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”

Jennifer Doudna, Ph.D., CRISPR Co-inventor

UC Berkeley, 2020

Publications

LATEST

FierceBiotech

JUN 2020

Biopharma tackles COVID-19, HIV and other viruses with gene and cell therapies

Excision Bio Announces Data Presentation at CROI from IND-Enabling Non-Human Primate Studies of EBT-001, Supporting a CRISPR Gene Editing Technology for HIV Elimination

PRESS RELEASE

MAR 2020

Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice

NATURE COMMUNICATIONS

JUL 2019

OUR

Partners

inquiries@excisionbio.com

988 Market Street
San Francisco, CA 94102
USA

1755 N. 13th Street #274
Philadelphia, PA 19122
USA

© 2020 Excision BioTherapeutics. All Rights Reserved.